NASDAQ:LRMR Larimar Therapeutics (LRMR) Stock Price, News & Analysis → CBOE shift unlocks new weekend income strategy (From DTI) (Ad) Free LRMR Stock Alerts $7.26 +0.06 (+0.83%) (As of 03/27/2024 ET) Add Compare Share Share Today's Range$7.08▼$7.4650-Day Range$4.26▼$13.2852-Week Range$2.18▼$13.68Volume442,161 shsAverage Volume578,587 shsMarket Capitalization$463.51 millionP/E RatioN/ADividend YieldN/APrice Target$16.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Larimar Therapeutics alerts: Email Address Larimar Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside124.8% Upside$16.33 Price TargetShort InterestHealthy2.55% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 3 Articles This WeekInsider TradingAcquiring Shares$37.52 M Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.17) to ($1.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.30 out of 5 starsMedical Sector694th out of 939 stocksPharmaceutical Preparations Industry324th out of 435 stocks 3.5 Analyst's Opinion Consensus RatingLarimar Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Larimar Therapeutics has a forecasted upside of 124.8% from its current price of $7.27.Amount of Analyst CoverageLarimar Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.55% of the outstanding shares of Larimar Therapeutics have been sold short.Short Interest Ratio / Days to CoverLarimar Therapeutics has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Larimar Therapeutics has recently increased by 221.63%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLarimar Therapeutics does not currently pay a dividend.Dividend GrowthLarimar Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LRMR. Previous Next 1.9 News and Social Media Coverage News SentimentLarimar Therapeutics has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Larimar Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 9 people have added Larimar Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Larimar Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $37,521,993.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Larimar Therapeutics is held by insiders.Percentage Held by Institutions91.92% of the stock of Larimar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Larimar Therapeutics are expected to decrease in the coming year, from ($1.17) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Larimar Therapeutics is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Larimar Therapeutics is -8.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLarimar Therapeutics has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Larimar Therapeutics Stock (NASDAQ:LRMR)Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is headquartered in Bala Cynwyd, Pennsylvania.Read More LRMR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LRMR Stock News HeadlinesMarch 19, 2024 | americanbankingnews.comLarimar Therapeutics (NASDAQ:LRMR) Given Market Outperform Rating at JMP SecuritiesMarch 18, 2024 | msn.com5 Stocks that Analysts Love in March 2024March 28, 2024 | Behind the Markets (Ad)The Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.March 16, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 callMarch 16, 2024 | markets.businessinsider.comBuy Rating Justified: Larimar Therapeutics’ Advancements Towards FDA Approval for FA Drug NomlabofuspMarch 14, 2024 | investorplace.comLRMR Stock Earnings: Larimar Therapeutics Misses EPS for Q4 2023March 14, 2024 | sfgate.comLarimar: Q4 Earnings SnapshotMarch 14, 2024 | benzinga.comRecap: Larimar Therapeutics Q4 EarningsMarch 28, 2024 | Behind the Markets (Ad)The Small Biotech with a BIG Cancer SolutionThere's a new cancer treatment so precise, it's been called a "smart bomb." One that can deliver a toxic payload directly to tumors while bypassing healthy cells.March 14, 2024 | finance.yahoo.comLarimar Therapeutics Inc (LRMR) Reports Full Year and Q4 2023 Financial ResultsMarch 14, 2024 | globenewswire.comLarimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp DevelopmentMarch 12, 2024 | markets.businessinsider.comBuy Rating on Larimar Therapeutics Backed by Promising Drug Progress for Friedreich’s AtaxiaMarch 12, 2024 | msn.com3 Best Stocks to Buy Now, 3/12/2024, According to Top AnalystsMarch 12, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Larimar Therapeutics (LRMR)March 11, 2024 | finance.yahoo.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’s AtaxiaMarch 11, 2024 | globenewswire.comLarimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's AtaxiaMarch 11, 2024 | msn.comLarimar Therapeutics to Present at Global Biopharma Conference in MiamiMarch 6, 2024 | globenewswire.comLarimar Therapeutics to Present at the Leerink Partners Global Biopharma ConferenceMarch 3, 2024 | bizjournals.comLocal life sciences companies reeled in more than $750M in stock sales in first two months of 2024February 23, 2024 | finance.yahoo.comLRMR Mar 2024 17.500 callFebruary 23, 2024 | finance.yahoo.comLRMR Apr 2024 10.000 putFebruary 22, 2024 | finance.yahoo.comLRMR Mar 2024 25.000 callFebruary 21, 2024 | markets.businessinsider.comBuy Rating Affirmed: Larimar Therapeutics’ Nomlabofusp Shows Potential in Friedreich’s Ataxia TreatmentFebruary 19, 2024 | msn.comInsider Trading: Larimar’s (NASDAQ:LRMR) Director Makes an Enormous PurchaseFebruary 19, 2024 | finance.yahoo.comLRMR Mar 2024 15.000 putFebruary 18, 2024 | msn.comLarimar Therapeutics Raises $172.5 Million in Public Offering to Propel Rare Disease ResearchFebruary 16, 2024 | finance.yahoo.comLarimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional SharesSee More Headlines Receive LRMR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LRMR CUSIPN/A CIK1374690 Weblarimartx.com Phone(844) 511-9056FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Target$16.33 High Stock Price Target$25.00 Low Stock Price Target$10.00 Potential Upside/Downside+124.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.83% Return on Assets-34.33% Debt Debt-to-Equity RatioN/A Current Ratio9.49 Quick Ratio9.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book3.91Miscellaneous Outstanding Shares63,800,000Free Float61,057,000Market Cap$463.51 million OptionableOptionable Beta0.95 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Carole S. Ben-Maimon M.D. (Age 65)CEO, President & Director Comp: $845.63kMr. Michael Celano CPA (Age 65)Secretary & CFO Comp: $562.62kMr. John BermanVice President of Finance & AdministrationMs. Jennifer Spokes JohanssonVice President of Legal & ComplianceDr. Russell G. Clayton Sr. (Age 63)D.O, Chief Medical Officer Dr. Gopi Shankar M.B.A. (Age 53)Ph.D., Chief Development Officer Mr. Francis Michael Conway CPAVP & ControllerMore ExecutivesKey CompetitorsStoke TherapeuticsNASDAQ:STOKAltimmuneNASDAQ:ALTEntrada TherapeuticsNASDAQ:TRDANeoleukin TherapeuticsNASDAQ:NLTXDianthus TherapeuticsNASDAQ:DNTHView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 27,516 shares on 3/11/2024Ownership: 3.314%Goldman Sachs Group Inc.Sold 1,734 shares on 3/1/2024Ownership: 0.305%James E FlynnBought 4,290,617 shares on 2/16/2024Total: $37.50 M ($8.74/share)GSA Capital Partners LLPSold 63,981 shares on 2/16/2024Ownership: 0.057%Nuveen Asset Management LLCBought 2,837 shares on 2/15/2024Ownership: 0.088%View All Insider TransactionsView All Institutional Transactions LRMR Stock Analysis - Frequently Asked Questions Should I buy or sell Larimar Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LRMR shares. View LRMR analyst ratings or view top-rated stocks. What is Larimar Therapeutics' stock price target for 2024? 4 brokers have issued twelve-month price objectives for Larimar Therapeutics' stock. Their LRMR share price targets range from $10.00 to $25.00. On average, they expect the company's stock price to reach $16.33 in the next twelve months. This suggests a possible upside of 124.8% from the stock's current price. View analysts price targets for LRMR or view top-rated stocks among Wall Street analysts. How have LRMR shares performed in 2024? Larimar Therapeutics' stock was trading at $4.55 at the beginning of 2024. Since then, LRMR stock has increased by 59.7% and is now trading at $7.2650. View the best growth stocks for 2024 here. Are investors shorting Larimar Therapeutics? Larimar Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 1,630,000 shares, an increase of 221.6% from the February 29th total of 506,800 shares. Based on an average trading volume of 570,900 shares, the days-to-cover ratio is presently 2.9 days. View Larimar Therapeutics' Short Interest. When is Larimar Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our LRMR earnings forecast. How were Larimar Therapeutics' earnings last quarter? Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced its earnings results on Friday, November, 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.64) by $0.28. Who are Larimar Therapeutics' major shareholders? Larimar Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Blue Owl Capital Holdings LP (7.78%), Verition Fund Management LLC (6.40%), Vanguard Group Inc. (3.31%), Vanguard Group Inc. (3.31%), Opaleye Management Inc. (1.42%) and Point72 Asset Management L.P. (1.03%). Insiders that own company stock include Frank E Thomas, James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton. View institutional ownership trends. How do I buy shares of Larimar Therapeutics? Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LRMR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Larimar Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.